Abstract
Limits of viability of extremely premature infants have recently been addressed both in Europe and the United States. These reports, which demonstrate frequent adverse outcome of infants born before 26 weeks of gestation, have not considered the impact of surfactant therapy. We reviewed records of 445 infants born between 23 and 36 weeks gestation who were admitted to our nursery following the availability of surfactant treatment in 1986 through 1992. Two hundred and eighty-five infants were treated with surfactant (Survanta, Ross Laboratories) as part of controlled, prospective trials or as routine treatment under Food and Drug Administration approval. One hundred and fifty-six infants were unable to be treated with surfactant, as either they received placebo therapy during prospective trials or were born prior to approval of routine surfactant use in the United States. Four additional infants born following the commercial availability of surfactant did not receive surfactant therapy. Survival of untreated infants was 56% compared to 75% in treated infants (P<0.001). Infants born at all gestational ages between 23 and 26 weeks had an increased likelihood of survival as a result of surfactant treatment. No differences in neurologic outcome between surfactant treated and non-treated infants were demonstrated at subsequent follow-up. We conclude that survival of extremely premature infants is improved following surfactant therapy and that subsequent neurologic outcome is not compromised as a result of this therapy.
Similar content being viewed by others
Abbreviations
- BPD :
-
bronchopulmonary dysplasia
- IVH :
-
intraventricular hemorrhage
- PVL :
-
periventricular leucomalacia
References
Bancalari E, Abdenour GE, Feller R, Gannon J (1979) Bronchopulmonary dysplasia: Clinical presentation. J Pediatr 95:819–823
Bose C, Corbet A, Bose G, et al (1990) Improved outcome at 28 days of age for very low birth weight infants treated with a single dose of a synthetic surfactant. J Pediatr 117:947–953
Corbet A, Bucciarelli R, Goldman S, et al (1991) Decreased mortality rate among small premature infants treated at birth with a single dose of synthetic surfactant: a multicenter controlled trial. J Pediatr 118:277–284
Crowley, P, Chalmers I., Keirse M (1990) The effects of corticosteroid administration before preterm delivery: an overview of the evidence from controlled trials. Br J Obstet Gynecol 97: 11–25
Ferrara TB, Hoekstra RE, Couser RJ, et al (1991) Effects of surfactant therapy on outcome of infants with birth weights of 600–750 grams. J Pediatr 119:455–457
Ferrara TB, Hoekstra RE, Couser RJ, et al (1994) Survival and follow-up of infants born at 23 to 26 weeks gestation: effects of surfactant therapy. J Pediatr (in press)
Hoekstra RE, Jackson JC, Myers TF, et al (1991) Improved neonatal survival following multiple doses of bovine surfactant in very premature neonates at risk of respiratory distress syndrome. Pediatr 88:10–18
Jobe, AH, Mitchell BR, Gunkel JH (1993) Beneficial effects of the combined use of prenatal corticosteroids and postnatal surfactant on preterm infants. Am J Obstet Gynecol 168:508–513
Papile, L, Burstein J, Burstein R, et al (1980) Incidence and evolution of subependymal and intraventricular hemorrhage in preterm infants: a study of infants with birth weight less than 1500 g. J Pediatr 92:529–534
Soll RF, Hoekstra RE, Fangman JJ, et al (1990) Multicenter trial of single dose modified surfactant extract (Survanta) for the prevention of respiratory distress syndrome. Pediatr 85:1092–1102
Stevenson D, Walther F, Long W, et al (1992) Controlled trial of a single dose of synthetic surfactant at birth in premature infants weighing 500 to 600 grams. J Pediatr 120:S3-S12
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hoekstra, R.E., Ferrara, T.B. & Payne, N.R. Effects of surfactant therapy on outcome of extremely premature infants. Eur J Pediatr 153 (Suppl 2), S12–S16 (1994). https://doi.org/10.1007/BF02179667
Issue Date:
DOI: https://doi.org/10.1007/BF02179667